| Date | Title | Description | |
|---|---|---|---|
| 02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
| 09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 11 Aug 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 3 August and 10 August 2023 | Download |
| 03 Aug 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 26 July 2023 and 2 August 2023 | Download |
| 28 Jul 2023 | On business and financial situation | ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® | Download |
| 05 Jul 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2023 | Download |
| 26 Jun 2023 | Other relevant information | The Company informs about the dividends payment | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 Oct 2018 | Share capital increases and reductions | Information on the registration in the Commercial Registry of Madrid of the notarial deed regarding the capital increase | Download |
| 05 Oct 2018 | Buy-back programmes, stabilisation and treasury stock | Information about the possibility that Jefferies International Limited carries out stabilisation transactions within the framework of the capital increase excluding pre-emptive subscription rights of the existing shareholders of Laboratorios Farmacéuticos Rovi, S.A. | Download |
| 04 Oct 2018 | Share capital increases and reductions | Directors’ Report and Independent Expert Report related to capital increase excluding preferential subscription rights | Download |
| 04 Oct 2018 | Liquidity contracts and specialists | The Company informs that has temporarily suspended liquidity agreement with JB Capital Markets, Sociedad de Valores, S.A.U. | Download |
| 04 Oct 2018 | Share capital increases and reductions | Information on price fixing and outcome of the private placement related to capital increase addressed to institutional investors, excluding preferential subscription rights | Download |